News: CSL UPDATE 1-CSL's half-year profit beats estimates on robust blood plasma collections, page-36

There are a lot of nuances in these trials so it's not as simple as you saying:

"...that injecting it into people with severe heart disease will prevent them going to hospital and dying."

All the people in the trials are going to die. The question is from what, and more significantly does CSL112 reduce the risk of further cardiovascular events or strokes in people at risk? The 90 day data from the Phase 3 trial suggests it does. In addition, the drug may offer a way of managing the condition in patients in combination with other treatments.

My only concern now is that CSL seems to be dragging its feet in releasing a final conclusion about CSL112. I recall mid 2022 was listed as a milestone but nothing eventuated. I can see that Covid may have delayed things so waiting another year looks likely.